Transintestinal elimination of ciprofloxacin.

This study identified the routes of elimination of ciprofloxacin in two groups of five subjects each: one of healthy volunteers; the other of patients with severe renal failure having mean creatinine clearance of 12 ml/min (range, 8-16 ml/min). Each subject received one dose of 200 mg ciprofloxacin infused intravenously (IV) over 30 min. In an effort to recover the total drug administered, all urine and feces were collected for 7 days following dosing. Blood samples were drawn at set intervals. Serum, urine, and feces were assayed for ciprofloxacin and metabolites by high-pressure liquid chromatography. The ciprofloxacin elimination half-life was 3.9 +/- 0.4 hr in the healthy volunteers and 11.2 +/- 2.5 hr in the patients with severe renal failure. The total 7-day recovery of ciprofloxacin and its metabolites in urine and feces ranged from 74.0% to 114.7% of the dose (mean, 96.3 +/- 14.1%) in normal subjects and from 48.5% to 109.1% (mean, 88.1 +/- 20.9%) in patients. The dose of ciprofloxacin recovered in urine was 65.3 +/- 10.7% in healthy subjects and 19.0 +/- 15.9% in impaired patients (reduction factor, 3.4). In contrast, the dose recovered in feces was 11.4 +/- 2.6% in the group of normal subjects and 37.2 +/- 12.5% in the group of patients with impaired renal function in a 3.3-fold increase.(ABSTRACT TRUNCATED AT 250 WORDS)

Treatment of superficial candidiasis with bifonazole 1% gel.

Sixty-one patients with superficial candidiasis, confirmed on entry by clinical examination and mycological culture, were treated with a single daily application of a 1% bifonazole gel over a period of 4 weeks. Patients were seen every week during treatment and then followed-up for 2 weeks. An overall assessment of response to treatment, based on the clinical and mycological culture findings at the 14-day follow-up visit, showed that the results were very good in 49 and moderate in 9 patients, with only 3 patients being considered as failing to respond. Local tolerance was very good, but burning was reported by 1 patient, burning and itching by 1, and ardor and irritation by one. All these side-effects occurred at the start of treatment and they subsided without interruption of bifonazole treatment.

Long-term effectiveness of BAY e 5009-nitrendipine in the treatment of mild and moderate arterial hypertension.

Thirty-seven white patients of both sexes were studied to determine the efficacy and tolerance of nitrendipine for long ambulatory treatment in patients suffering from mild to moderate essential arterial hypertension whose response to the drug had been effective in a previous study. They all suffered from mild essential arterial hypertension, with diastolic arterial blood pressure (DBP) of 95-104 mm Hg, and moderate arterial hypertension with DBP of 105-114 mm Hg, in WHO Stage I or II, according to the clinical, radiological, electrocardiographic, and ophthalmoscopic examinations. In a previous study, all of them had been subjected to tensional controls, performed hourly during an 8-h period to assess their hypertension. Later, they were treated with increasing doses of nitrendipine, administered once or twice daily, until DBP figures under 90 mm Hg were obtained in at least five of the eight controls of each daily profile. All of them agreed to take part in the present research and underwent heart rate and arterial blood pressure controls in supine and standing position every 14 days during 24 periods. Simultaneous clinical and weight controls were performed. Moreover, an electrocardiogram was made every 28 days, and blood and urine tests were performed every 3 months. Of the 37 patients, 31 completed the 24 periods of 2 weeks each. Therefore, of 888 possible controls only 837 controls were made and submitted for assessment. Eighteen patients (48.6%) went on with the initial dose throughout the study or were able to reduce it. Eleven (29.7%) had to increase it, and in eight cases (21.6%) it was either increased or reduced.(ABSTRACT TRUNCATED AT 250 WORDS)

Uretritis gonococica aguda. Informe sobre 69 casos tratados con una nueva ureido-penicilina. / Acute gonoccocic urethritis. Report of 69 cases treated with a new ureido-penicillin

Se exponen los resultados obtenidos en el tratamiento de los primeros sesenta y nueve casos de gonococia aguda tratados con dos diferentes dosis unicas, por via intramuscular, de una nueva ureido-penicilina,el BAY f.1353.Creemos que no enmascara la lues a las dosis administradas. El resultado clinico y bacteriologico fue exitoso en el 100% de los casos, con las diferentes dosis administradas.No se presentaron fenomenos secundarios y la tolerancia local y general fue muy buena

Uretritis gonococica aguda. Informe sobre 69 casos tratados con una nueva ureido-penicilina. / Acute gonoccocic urethritis. Report of 69 cases treated with a new ureido-penicillin

Se exponen los resultados obtenidos en el tratamiento de los primeros sesenta y nueve casos de gonococia aguda tratados con dos diferentes dosis unicas, por via intramuscular, de una nueva ureido-penicilina,el BAY f.1353.Creemos que no enmascara la lues a las dosis administradas. El resultado clinico y bacteriologico fue exitoso en el 100% de los casos, con las diferentes dosis administradas.No se presentaron fenomenos secundarios y la tolerancia local y general fue muy buena

Enrichment in spontaneous and complement dependent rosette forming cell populations using Ficoll-Hypaque gradient centrifugation.

Peripheral blood human T (TL) and B (BL) lymphocytes were separated by continuous Ficoll-Hypaque (FH) gradients. BL were found at the 1050 density interfase (70.5% EAC rosettes) with no TL (0% EAC rosettes); while at the 1068 density interfase there was an enrichment of TL (68% E rosettes) with very few BL (8.5% EAC rosettes).